MedTrace Logo

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2025-12-11

No results posted yet for this study

Summary

Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.

Conditions

Interventions

DRUG

Continue PD-1/PD-L1 Inhibitors treatment

Continued treatment with PD-1/PD-L1-1 inhibitor

OTHER

Discontinue PD-1/PD-L1-1 inhibitor

Discontinued treatment with PD-1/PD-L1-1 inhibitor

Sponsors & Collaborators

  • Dan Zandberg

    lead OTHER

Principal Investigators

  • Dan Zandberg, MD · UPMC Hillman Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2025-10-14
Completion
2025-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04157985 on ClinicalTrials.gov